Royal Fund Management’s Quest Diagnostics DGX Stock Holding History

Royal Fund Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-98	Closed	-$7K	–	245
2020 Q1	$7K	Hold	98	–	–	﹤0.01%	402
2019 Q4	$10K	Hold	98	–	–	﹤0.01%	418
2019 Q3	$10K	Hold	98	–	–	﹤0.01%	388
2019 Q2	$9K	Hold	98	–	–	﹤0.01%	393
2019 Q1	$8K	Hold	98	–	–	﹤0.01%	384
2018 Q4	$8K	Hold	98	–	–	﹤0.01%	357
2018 Q3	$10K	Buy	+98	New	+$10.7K	﹤0.01%	326

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FMI

Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Fund Management's DGX Position: Q2 2020 in Review

Royal Fund Management sold out of Quest Diagnostics (DGX) in Q2 2020, closing a stake of 98 shares — an estimated $7K sold.

Royal Fund Management first reported a position in DGX in Q3 2018 and held it in 7 quarters. The position peaked at $10K in Q4 2019. 748 funds tracked by Wall St. Rank hold DGX as of Q2 2020.

Royal Fund Management reported no remaining Quest Diagnostics position as of Q2 2020 after selling out during the quarter.
Royal Fund Management sold 98 Quest Diagnostics shares in Q2 2020, an estimated $7K.
Royal Fund Management first reported a position in Quest Diagnostics in Q3 2018 and held it in 7 quarters.
Royal Fund Management's Quest Diagnostics position peaked at $10K in Q4 2019.
748 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2020.

Based on Royal Fund Management's 13F filing for Q2 2020, filed 6 Aug 2020.